TVTX Q4 2018 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TVTXTravere Therapeutics, Inc.

$3B

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$44M+3.8% YoY

Gross Profit

$42M96.3% margin

Operating Income

-$5M-11.4% margin

Net Income

-$7M-17.0% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

+7.5%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$7M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$709M

Total Liabilities

$391M

Stockholders' Equity

$318M

Cash & Equivalents

$103M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$44M	$42M	+3.8%
Gross Profit	$42M	$41M	+2.8%
Operating Income	-$5M	-$15M	+67.2%
Net Income	-$7M	-$18M	+57.7%

Revenue Segments

Thiola License

$24M54%

Bile Acid Products

$20M46%